Welcome to our dedicated page for Viaderma news (Ticker: VDRM), a resource for investors and traders seeking the latest updates and insights on Viaderma stock.
ViaDerma, Inc. (VDRM) is a biotechnology innovator advancing transdermal drug delivery systems and topical pharmaceutical solutions. This page serves as the definitive source for ViaDerma-related news, providing investors and industry observers with timely updates on corporate developments, regulatory milestones, and market expansion activities.
Visitors will find comprehensive coverage of ViaDerma's strategic initiatives, including new product launches, licensing agreements, and research advancements in wound care and pain management. The curated news collection enables stakeholders to track the company's progress in addressing global healthcare challenges through its proprietary drug delivery platforms.
Key updates include earnings announcements, partnership disclosures, and international regulatory approvals that underscore ViaDerma's position in specialty pharmaceuticals. All content is verified for accuracy and relevance to maintain its value as a long-term reference.
Bookmark this page to stay informed about ViaDerma's innovations in transdermal technology and its expanding presence across emerging markets. Check back regularly for objective reporting on operational achievements that shape the company's trajectory in biotechnology.
ViaDerma (OTC Pink: VDRM) has announced the opening of a satellite office in Dubai to support its Middle Eastern expansion, complying with local regulations requiring physical presence for commercial operations. The company also reports progress in India, where it recently met with officials from a large that works closely with the Indian government. ViaDerma's registration application for its topical antibiotic solution in India is in its final stages, with approval expected in Q1 2025.
The potential market entry into India, with its population of approximately 1.4 billion people, represents a significant opportunity for ViaDerma's topical antibiotic products. The company's CEO, Dr. Christopher Otiko, expressed confidence in breakout growth for 2025, building on the company's 2024 achievements.
ViaDerma (OTC Pink: VDRM), a transdermal drug delivery and topical antibiotic products company, reports significant achievements in 2024. The company has expanded its workforce to 13 professionals, with 6 employees in the United States and 7 abroad, operating across seven countries. A major milestone includes the successful completion of a one-million-unit order to Nigeria, delivered in two shipments of 500,000 units each in August and October 2024. The company positions these achievements as groundwork for further expansion in 2025.
ViaDerma, Inc. (OTC Pink: VDRM) reported strong financial results for Q2 2024, achieving positive net income and significant cash flow growth. Key highlights include:
- Steady revenues of $300,191 for H1 2024
- Net income of $54,008 for the six-month period, a 171.5% increase from the previous year
- Cash reserves surged to $826,175, a 7,972% increase from year-end 2023
- Total liabilities reduced by 5.3% to $1,096,509
The company's lead product, Vitastem, an FDA-registered topical antibiotic, continues to gain market traction. ViaDerma is advancing its product pipeline in anti-aging skincare, pain management, and other areas. The company is also adopting a wholesale distribution model and exploring joint ventures to expand its market presence.
ViaDerma (OTC: VDRM) has successfully shipped 500,000 units of its tetracycline-based topical antibiotic to Nigeria, marking a significant milestone in its international expansion. The shipment was completed as planned by the end of August 2024. A second shipment of an additional 500,000 units is expected to be dispatched by the end of October 2024, demonstrating the company's commitment to consistent supply.
CEO Dr. Christopher Otiko recently returned from a productive follow-up trip to Dubai, where he engaged with key partners, solidifying plans to expand distribution across the Middle East. ViaDerma's innovative products, including patented transdermal delivery systems, have been well-received in international markets, addressing the growing need for effective wound care solutions in underserved regions.
ViaDerma, Inc. (OTC: VDRM) has announced a significant milestone in its global expansion efforts. The company is preparing to ship 500,000 units of its flagship tetracycline-based topical antibiotic to Nigeria by the end of August 2024, with a follow-up delivery expected in November 2024. This move marks ViaDerma's strategic push into the African market.
Additionally, ViaDerma has begun the registration process in Kenya, Namibia, and Tanzania, signaling its entry into East and Southern Africa. The company is also preparing registration applications for seven other countries across Africa, Europe, and the Middle East. CEO Dr. Christopher Otiko will be traveling to Dubai to finalize key initiatives with regional partners, focusing on strengthening partnerships and expanding distribution throughout the Middle East.
ViaDerma, Inc. (OTC Pink: VDRM) has announced significant developments in its global expansion strategy. The company has finalized distribution agreements with two leading companies in Dubai, aimed at expanding the availability of its flagship topical antibiotic product, Vitastem, in the Middle East and Eastern Europe. To support this growth, ViaDerma has made six key hires, including a Business Development Analyst, Project Manager, HR Specialist, Fractional COO, and a Regulatory Specialist with FDA experience. A new Chief Technology Officer is also set to join soon.
Dr. Christopher Otiko, President of ViaDerma, expressed optimism about the company's future growth prospects and hinted at a forthcoming announcement regarding a large international shipment of Vitastem. These strategic moves position ViaDerma for significant expansion beyond the United States market.
ViaDerma (OTC Pink: VDRM) released its quarterly report for the period ending March 31, 2024, showcasing significant financial improvements. The company experienced a 3700% increase in cash on hand, rising from $9,933 to $377,901 compared to the previous year.
Gross profits saw a slight uptick, while operating expenses were reduced by 52%, from $93,356 to $44,744. In a noteworthy move, CEO Dr. Christopher Otiko provided a $700,000 loan to the company, which he repaid in full by May 28, 2024.
ViaDerma currently holds approximately $1 million in cash, sufficient to fund ongoing operations without incurring debt. Additionally, the company is hiring three new full-time employees to boost international sales, reflecting its robust financial health.
ViaDerma, Inc. (OTC Pink: VDRM) has announced the brand name Nupelo for its upcoming minoxidil hair regrowth product. The company recently submitted an application for FDA registration, expected to be completed within weeks. Nupelo will utilize ViaDerma’s proprietary dual carrier transdermal delivery technology, aimed at effectively regrowing hair rather than just reducing hair loss. The product is set to launch for purchase online by the end of Q2 2023, with availability on various platforms including nupelo.com. CEO Dr. Chris Otiko highlighted the speed and effectiveness of the development process.
